This Market Spotlight report covers the Fibromyalgia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, prevalence data, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• The approved drugs in the fibromyalgia space target dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, serotonin reuptake, and voltage-gated calcium channels. All of the marketed drugs for fibromyalgia are administered via the oral route.
• The majority of industry-sponsored drugs in active clinical development for fibromyalgia are in Phase II. Therapies in development for fibromyalgia focus on a wide variety of targets. These drugs are most commonly administered via the oral route.
• High-impact upcoming events in the fibromyalgia space comprise topline Phase III trial results for Tonmya, topline Phase II trial results for NYX-2925, and topline Phase IIb trial results for IMC-1.
• The overall likelihood of approval of a Phase I pain asset is 5.3%, and the average probability a drug advances from Phase III is 55.5%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 10.1 years in the overall neurology space.
• The distribution of clinical trials across Phase I–IV indicates that the majority of trials for fibromyalgia have been in the late phases of development, with 68% of trials in Phase III–IV, and 32% in Phase I–II.
• The US has a substantial lead in the number of fibromyalgia clinical trials globally. Germany, Spain, and the UK lead the major European markets, while India has the top spot in Asia.
• Clinical trial activity in the fibromyalgia space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for fibromyalgia, with 21 trials.
• Pfizer leads industry sponsors with the highest overall number of clinical trials for fibromyalgia, followed by AbbVie.